The Shigella Vaccines Market is estimated to be valued at US$574.20 Million in 2021 and is expected to exhibit a CAGR Of 6.4% over the forecast period 2022 To 2028, as highlighted in a new report published by Coherent Market Insights.
The Shigella Vaccines Market caters to the demand for preventive vaccines against Shigella infections. Shigella is a bacteria that causes shigellosis, a highly contagious intestinal infection. The business description of this market revolves around the development and distribution of vaccines that can protect individuals from Shigella infections. These vaccines are designed to stimulate the immune system and provide immunity against the bacteria. The market focuses on delivering effective vaccines that can prevent the transmission and reduce the burden of Shigella infections worldwide.
The Shigella Vaccines Market is driven by two key factors. Firstly, the increasing prevalence of Shigella infections globally is creating a significant demand for preventive vaccines. Shigella is responsible for a significant number of diarrheal cases, especially in low-income countries. The need for preventing these infections is driving the demand for Shigella vaccines.
Secondly, the growing awareness of the benefits of vaccination and the efforts of government and non-governmental organizations to promote vaccination programs are driving the market growth. Increasing investments in research and development activities to develop advanced vaccines with improved efficacy and safety profiles are further boosting market growth.
In conclusion, the Shigella Vaccines Market is poised for high growth due to the increasing prevalence of Shigella infections and the growing demand for preventive vaccines.
The Shigella Vaccines market can be segmented based on type and end-use. In terms of type, the market can be divided into conjugate vaccines, live attenuated vaccines, and subunit vaccines. Among these, the subunit vaccines segment is expected to dominate the market. This dominance can be attributed to factors such as better safety profile and ease of production compared to other types of vaccines. Subunit vaccines offer targeted immune response by inducing antigen-specific antibodies, which makes them an effective preventive measure against Shigella infections. Additionally, the rising prevalence of Shigella infections and the increasing awareness about the importance of vaccination are driving the demand for subunit vaccines.
Political: Governments across the globe are actively promoting vaccination programs to prevent the spread of infectious diseases, including Shigella infections. This creates a favorable political environment for the Shigella Vaccines market.
Economic: The growing healthcare expenditure and the rising disposable income of individuals are driving the demand for Shigella vaccines. Moreover, the cost-effectiveness of vaccination programs compared to the cost of treating Shigella infections is further boosting market growth.
Social: Increasing awareness about the importance of vaccination and the benefits of preventing Shigella infections through immunization is positively influencing the market. Moreover, growing concerns regarding the impact of Shigella infections on public health are driving individuals to opt for vaccination.
Technological: Advances in vaccine formulation and production technologies are facilitating the development of more effective and safer Shigella vaccines. These advancements are driving innovation in the market and opening up new growth opportunities.
The global Shigella Vaccines Market is expected to witness high growth, exhibiting a CAGR of 6.4% over the forecast period. This growth can be attributed to increasing government support for vaccination programs to prevent the spread of Shigella infections. Furthermore, the rising prevalence of Shigella infections and the growing awareness about the importance of vaccination are driving the demand for Shigella vaccines.
In terms of regional analysis, North America is expected to be the fastest-growing and dominating region in the Shigella Vaccines market. This can be attributed to factors such as the presence of major key players, government initiatives promoting immunization, and the high incidence of Shigella infections in the region.
Key players operating in the Shigella Vaccines market include MSD Wellcome Trust Hilleman Laboratories Pvt. Ltd., Novartis (Novartis Vaccines Institute for Global Health), and GlaxoSmithKline plc. These key players are actively involved in research and development activities to develop innovative and effective Shigella vaccines. They are also focusing on strategic collaborations and partnerships to expand their market presence and gain a competitive edge.
- Source: Coherent Market Insights, Public sources, Desk research
- We have leveraged AI tools to mine information and compile it